We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026

LabCorp to Acquire Certain Assets of Quest Diagnostics

By HospiMedica staff writers
Posted on 03 Mar 2003
Under an agreement made in early February 2003, Laboratory Corp. More...
of America (LabCorp, Burlington, NC, USA) agreed to pay US$4.5 million for certain assets of Quest Diagnostics (Teterboro, NJ, USA), following the completion of Quest's acquisition of Unilab Corp. (Tarzana, CA, USA). Quest's acquisition of Unilab for $813 million was recently approved by US regulators and is now completed.

The LabCorp purchase is designed to satisfy the concern of regulators that Quest's purchase of Unilab might harm competition of laboratory services in northern California. The assets LabCorp is acquiring include the leases for 46 patient service centers and contracts with independent physician associations in California (USA). LabCorp has been a pioneer in commercializing new diagnostic technologies and said it is the first US clinical laboratory to fully embrace genomic testing.

LabCorp combines its expertise in clinical testing technology with its Centers of Excellence. These include the Center for Molecular Biology and Pathology (Research Triangle Park, NC, USA), its National Genetics Institute in Los Angeles (CA, USA), its Center for Esoteric Testing (Burlington, NC, USA), and its ViroMed center in Minneapolis (MN, USA). The company had revenues of $2.2 billion in 2001.

"Strategically, the business acquired in this very important market also provides LabCorp with a solid foundation for generating additional revenues through both the routine physician market as well as business development activities in esoteric testing,” said Richard L. Novak, executive vice president and CEO of LabCorp.




Related Links:
LabCorp
Quest Diagnostics

Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.